Buyout rumors, short covering propel surge in TG Therapeutics

 

• X chatter and market sources cite active M&A interest with multiple bidders including Jazz Pharmaceuticals.
• Speculation of acquisition price between $85-$100 per share fueled intraday buying to ~$56.40.
• Over 22 million shares in short interest triggered covering ahead of the weekend.
• Builds on strong BRIUMVI sales momentum, Q2 revenue beat, and raised 2026 guidance to ~$950M.
• Recent analyst actions and guru buying (5 of 6 adding shares) support underlying optimism.
• No official company confirmation or new clinical data announced on August 21.

https://finviz.com/stock?t=TGTX&p=d